Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020

August 17th, 2020

Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020

 Chester, New Jersey, August 17, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in the World Orphan Drug Conference USA.  Hillstream will be providing updates on recent corporate developments as well as outlining near-term activities anticipated in 2H-2020.  Details about the conference are as follows:

  Where:   Virtual – World Orphan Drug Conference
  Presentation Details:   August 17, 2020 – 5pmET
  On Demand Access:   August 17, 2020 – September 27, 2020
  Conference Dates:   Monday, August 24 – Thursday, August 27, 2020
  Conference Website:   World Orphan Drug Conference USA

A webcast of the Hillstream’s presentation will be available to registered attendees starting on Monday, August 17, 2020 on the World Orphan Drug Conference website – https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.

One-on-one meetings can be arranged through the World Orphan Drug Conference USA’s 1:1 virtual meeting feature.  Investors wishing to virtually connect with Hillstream outside of the World Orphan Drug Conference USA can book appointments directly through Hillstream’s investor relations representative, Jennifer K. Zimmons, Ph.D. jzimmons@zimmonsic.com or +1.917.214.3514.

About Hillstream BioPharma Inc.

Hillstream BioPharma Inc. (“Hillstream”) is a development-stage company advancing improved therapies for patients with cancer via a unique nanoparticle delivery platform. Hillstream’s competitive advantage is to enhance the safety and efficacy of oncology therapies by encapsulating them in its proprietary polymeric injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows Hillstream to build a strong patent estate and seek both FDA Orphan Drug Designation and more rapid FDA review in specific indications.  For more information, please visit tharimmune.com.

About World Orphan Drug Conference

The 10th annual World Orphan Drug Congress USA will bring together rare disease stakeholders virtually in August, 2020. As the largest rare disease conference globally with over 1,500 attendees, we are excited to virtually gather leading industry, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers to meet, brainstorm and dialogue on ways to advance orphan drug development and improve access to lifesaving therapies.  With more anticipated attendees than the physical event, World Orphan Drug Congress USA team is looking forward to delivering a fully virtual, interactive and valuable experience. Visit   World Orphan Drug Conference USA

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Hillstream BioPharma Inc.

Randy Milby
President & CEO
Hillstream Biopharma Inc.
Tel: +1 302.743.2995
Email: rmilby@tharimmune.com

 Investor Contact:
Jennifer K. Zimmons, Ph.D.

Investor Relations
Zimmons International Communications
Tel: +1 917.214.3514
Email: jzimmons@zimmonsic.com
Source: Hillstream BioPharma Inc.